激素受体阳性/HER2阴性早期乳腺癌内分泌治疗研究进展OA

Hormone receptor(HR)-positive/HER2-negative early breast cancer is the most common subtype of breast cancer,and endocrine therapy serves as the cornerstone of adjuvant treatment.In recent years,with the publication of key clinical trials such as SOFT,TEXT,and monarchE,and breakthroughs in novel agents studies like lidERA,the endocrine therapy strategy for HR-positive/HER2-negative early breast cancer has evolved toward increased precision and intensity.This article systematically reviews the latest advances in endocrine therapy,focusing on the consolidation of ovarian function suppression as a standard for high-risk premenopausal patients with updated follow-up evidence,the benefit-risk assessment of extended endocrine therapy,and the current application and interdrug differences of CDK4/6 inhibitors in the adjuvant setting.This manuscript also addresses existing challenges,including optimizing treatment-related quality of life and precisely identifying beneficiary populations,and briefly introduces the clinical trial progress of novel agents,such as oral selective estrogen receptor degraders.Furthermore,it outlines evidence-based strategies for ovarian protection during chemotherapy and fertility preservation for young patients.This review aims to provide clinicians with a comprehensive perspective,balancing the pursuit of maximal efficacy with patients'long-term quality of life and individualized needs.